- Home
- AZN vs DHR Comparison
AZN vs DHR Comparison
Compare AZN & DHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AZN
- DHR
- Stock Information
- Founded
- AZN 1992
- DHR 1969
- Country
- AZN United Kingdom
- DHR United States
- Employees
- AZN N/A
- DHR N/A
- Industry
- AZN Biotechnology: Pharmaceutical Preparations
- DHR Industrial Machinery/Components
- Sector
- AZN Health Care
- DHR Industrials
- Exchange
- AZN Nasdaq
- DHR Nasdaq
- Market Cap
- AZN 212.2B
- DHR 170.9B
- IPO Year
- AZN 1993
- DHR N/A
- Fundamental
- Price
- AZN $65.35
- DHR $228.65
- Analyst Decision
- AZN Buy
- DHR Buy
- Analyst Count
- AZN 10
- DHR 17
- Target Price
- AZN $88.80
- DHR $288.00
- AVG Volume (30 Days)
- AZN 5.6M
- DHR 3.5M
- Earning Date
- AZN 02-06-2025
- DHR 01-28-2025
- Dividend Yield
- AZN 2.27%
- DHR 0.47%
- EPS Growth
- AZN 9.79
- DHR N/A
- EPS
- AZN 4.15
- DHR 5.24
- Revenue
- AZN $51,206,000,000.00
- DHR $23,742,000,000.00
- Revenue This Year
- AZN $17.69
- DHR $0.39
- Revenue Next Year
- AZN $7.95
- DHR $5.80
- P/E Ratio
- AZN $30.78
- DHR $43.11
- Revenue Growth
- AZN 13.81
- DHR 12.92
- 52 Week Low
- AZN $60.47
- DHR $222.53
- 52 Week High
- AZN $87.68
- DHR $281.70
- Technical
- Relative Strength Index (RSI)
- AZN 41.89
- DHR 37.76
- Support Level
- AZN $66.14
- DHR $232.00
- Resistance Level
- AZN $67.47
- DHR $237.96
- Average True Range (ATR)
- AZN 0.93
- DHR 4.61
- MACD
- AZN -0.03
- DHR -0.09
- Stochastic Oscillator
- AZN 30.45
- DHR 19.88
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its sales.
About DHR Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.